WHO. World Health Organization. HIV and AIDS- Key facts. 2023.
GAC, Ghana AIDS. Commission: People Living with HIV in Ghana. 2023.
WB. The World Bank. Prevalence of HIV, total (% of population ages 15–49.)– Ghana 2021.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel. JAMA. 2006;296(7):827–43.
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel. JAMA. 2023;329(1):63–84.
Garone D, Conradie K, Patten G, Cornell M, Goemaere E, Kunene J, et al. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha, South Africa. South Afr J HIV Med. 2013;14(4):170–5.
Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, et al. Increasing the use of second-line therapy is a cost‐effective approach to prevent the spread of drug‐resistant HIV: a mathematical modelling study. J Int AIDS Soc. 2014;17(1):19164.
Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resource-limited settings. J Infect Dis. 2013;207(suppl2):S49–56.
Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, et al. HIV drug resistance detected during low-level viremia is associated with subsequent virologic failure. AIDS. 2014;28(8):1125.
NACP-Ghana. National AIDS Control Programme: 2019 Annual Report-June 2020. 2019:38.
NACP-Tanzania. National AIDS Control Program United Republic of Tanzania: National Guidelines for the Management of HIV and AIDS. 2019.
Jenkins SY, Resar D, Panos Z, Staple A, Watkins M, Ripin D, et al. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low‐and middle‐income countries. J Int AIDS Soc. 2023;26:e26101.
Meyer-Rath G, Jamieson L, Pillay Y. What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023;26:e26106.
Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007;60(2/3):113.
Sia D, Onadja Y, Hajizadeh M, Heymann SJ, Brewer TF, Nandi A. What explains gender inequalities in HIV/AIDS prevalence in sub-saharan Africa? Evidence from the demographic and health surveys. BMC Public Health. 2016;16(1):1–18.
Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8(1):1–8.
Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis. 2006;19(6):607–14.
Organization WH. Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. 2021. https://iris.who.int/bitstream/handle/10665/340190/9789240022232-eng.pdf; [Accessed March 14, 2024].
Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023.
Montarroyos UR, Miranda-Filho DB, César CC, Souza WV, Lacerda HR, Militão Albuquerque MFP, et al. Factors related to changes in CD4 + T-cell counts over time in patients living with HIV/AIDS: a multilevel analysis. PLoS ONE. 2014;9(2):e84276.
Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18(11):1529–37.
Aggleton P, Yankah E, Crewe M. Education and HIV/AIDS—30 years on. AIDS Educ Prev. 2011;23(6):495–507.
Govathson C, Ndlovu N, Rambally-Greener L, Schmucker L, Chetty-Makkan CM, Miot J et al. Increasing HIV treatment literacy among people living with HIV using a novel health communication aid: evidence from KwaZulu Natal province, South Africa. medRxiv. 2023:2023.06. 15.23291430.
Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir-and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79(6):3329–38.
Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189(10):1802–10.
Chimukangara B, Lessells RJ, Sartorius B, Gounder L, Manyana S, Pillay M, et al. HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa. J Global Antimicrob Resist. 2022;29:468–75.
Bircher RE, Ntamatungiro AJ, Glass TR, Mnzava D, Nyuri A, Mapesi H, et al. High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania–A prospective cohort study. PLoS ONE. 2020;15(1):e0227600.
Add Comment